---
title: "Daan Gene Co.,Ltd. (002030.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002030.SZ.md"
symbol: "002030.SZ"
name: "Daan Gene Co.,Ltd."
industry: "Biotechnology"
datetime: "2026-05-21T20:57:56.070Z"
locales:
  - [en](https://longbridge.com/en/quote/002030.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002030.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002030.SZ.md)
---

# Daan Gene Co.,Ltd. (002030.SZ)

## Company Overview

Daan Gene Co., Ltd., together with its subsidiaries, researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables in China. It operates through two segments, Biological Products and Related Business and Financial Business. The company offers reagents for hepatitis virus, sexually transmitted infections, blood screening, digestive pathogens, coronavirus disease (COVID-19), pharmacogenomics, viral transport medium, human papillomavirus, human immunodeficiency virus, respiratory infections, public health, tumor maker, and nucleic acid extraction, as well as polymerase chain reaction, sample preparation, and nucleic extraction systems for molecular diagnosis; COVID-19 rapid test kit and chemiluminescence immunoassay analyzers for immunoassay; liquid based cytology production and automatic sample transfer machines for pathology tests; and auto biochemistry analyzers and chemistry reagents for clinical chemistry. It also provides medical laboratory and health consultation services, such as genetic susceptibility gene testing, tumor marker testing, cervical cancer screening, routine physical examination, and other health services.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.daangene.com](https://www.daangene.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: D (0.67)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 70 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -10.43% |  |
| Net Profit YoY | -75.94% |  |
| P/B Ratio | 1.37 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 9637146569.38 |  |
| Revenue | 736545881.24 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -11.96% | D |
| Profit Margin | -121.34% | E |
| Gross Margin | 30.77% | C |
| Revenue YoY | -10.43% | E |
| Net Profit YoY | -75.94% | E |
| Total Assets YoY | -12.15% | E |
| Net Assets YoY | -11.32% | E |
| Cash Flow Margin | -34.68% | E |
| OCF YoY | -10.43% | E |
| Turnover | 0.08 | E |
| Gearing Ratio | 12.81% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Daan Gene Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-10.43%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-75.94%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.37",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "9637146569.38",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "736545881.24",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-11.96%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-121.34%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "30.77%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-10.43%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-75.94%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-12.15%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-11.32%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-34.68%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-10.43%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.08",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "12.81%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -10.16 | 49/81 | - | - | - |
| PB | 1.29 | 9/81 | 1.20 | 1.15 | 1.09 |
| PS (TTM) | 12.32 | 57/81 | 12.01 | 11.35 | 10.85 |
| Dividend Yield | 0.00% | - | 0.25% | 0.25% | 0.24% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | Biocytogen (688796.SH) | A | A | E | B | A | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002030.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002030.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002030.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002030.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**